Vineet Laboratories Limited

Equities

VINEETLAB

INE505Y01010

Pharmaceuticals

Market Closed - NSE India S.E. 07:43:56 2024-06-14 am EDT 5-day change 1st Jan Change
61.76 INR +0.54% Intraday chart for Vineet Laboratories Limited +5.93% -24.36%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Vineet Laboratories CEO Resigns MT
Vineet Laboratories Limited Announces Resignation of Satish Pandurang Samant as Executive Director CI
Vineet Laboratories Limited Announces Resignation of Satish Pandurang Samant as Chief Executive Officer CI
Vineet Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
Vineet Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Vineet Laboratories Limited Announces Appointment of Mr. Rameshkumar Bandari as Company Secretary and Compliance Officer CI
Vineet Laboratories Limited Reports Earnings Results for the Half Year Ended September 30, 2023 CI
Vineet Laboratories Limited Announces Resignation of Nirosha Ravikanti as Company Secretary / Compliance Officer of the Company CI
Vineet Laboratories Names CEO MT
Vineet Laboratories Limited Appoints Mr. Satish Pandurang Samant as Chief Executive Officer CI
Vineet Laboratories Limited Appoints Mr. Satish Pandurang Samant as an Additional Executive Director CI
Vineet Laboratories Limited Appoints Ranga Raju Alluri as Non-Executive Director CI
Vineet Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Vineet Laboratories Limited Announces Board Changes CI
Vineet Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
Vineet Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Vineet Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Chart Vineet Laboratories Limited
More charts
Vineet Laboratories Limited is engaged in the business of drug intermediates and bulk drugs. The Company specializes in pharmaceutical intermediates and fine chemicals. Its active pharmaceutical ingredient (API) intermediates include Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, and Piroctone Olanine. Its fine chemicals and reagents include Isopropyl-beta-D-thiogalactopyranoside, 4-Nitrophenyl phosphate disodium salt, 5-Bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (X-Gal), 5-Acetyl thiophene-2-carboxilic acid, n-Butyl Lithium, n-Butyl magnesium chloride, 3-Furaldehyde, 3-bromofuran, 1-methyl-imidazole-2-carboxaldehyde, 6-Aminouracil, Ethyldiazo acetate, and Phenylboronic acid. It also exports API intermediates, fine chemicals, and custom synthesis molecules.
More about the company